Pyridam Farma Tbk PT
Pyridam Farma Tbk PT is an Indonesian pharmaceutical company that develops, produces, and distributes a range of pharmaceutical products, primarily generating revenue through the sale of these products to healthcare providers and consumers.
Business. Pyridam Farma Tbk PT (PYFA.JK) is an Indonesian pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Indonesia and primarily listed on the Indonesia Stock Exchange (IDX). Specific details regarding its operating segments and geographic revenue mix are not disclosed.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Pyridam Farma Tbk PT (PYFA.JK) is an Indonesian pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Indonesia and primarily listed on the Indonesia Stock Exchange (IDX). Specific details regarding its operating segments and geographic revenue mix are not disclosed.
The company's capital structure is highly leveraged, with a debt-to-equity ratio of 6.31, indicating a significant reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.24, suggesting limited short-term liquidity cushion. The company's price-to-book ratio of 3.46 implies that the market values the company at a premium to its book value, but this is not supported by positive earnings or cash flow. Free cash flow is negative at -256.15 billion IDR, and operating cash flow is also negative at -364.28 billion IDR, indicating ongoing cash burn.
Profitability metrics are weak, with a return on equity of -0.495 and a return on assets of -0.0561, both significantly below industry norms. The company reported a net loss of 379.67 billion IDR and an operating loss of 217.20 billion IDR, reflecting poor operational performance. Gross profit of 583.14 billion IDR is insufficient to cover operating expenses, contributing to the net loss.
Geographic and segment exposure is not explicitly detailed in the available data, but the company operates primarily in Indonesia. Revenue concentration in a single market increases exposure to local economic and regulatory risks. The absence of disclosed international operations or segment breakdowns limits visibility into diversification strategies.
Growth trajectory is negative, with no clear indication of improvement in the near term. The company's operating income and net income are both in negative territory, and there is no evidence of a turnaround in the current fiscal year. The lack of positive cash flow and the high debt burden suggest that the company may face challenges in sustaining operations without external financing.
Risk factors include liquidity constraints and the potential for dilution, although the latter is currently assessed as low. The company's negative net cash position after subtracting total debt is a key flag, indicating a high risk of insolvency if cash flow does not improve. The absence of a clear path to profitability or debt reduction increases the risk profile.
Recent events include the publication of the latest financial results, which show continued losses and negative cash flow. No significant corporate actions or strategic initiatives have been disclosed in the available data. The company's financial health remains a concern, with no immediate signs of improvement in its operational or financial performance.
- Pyridam Farma Tbk PT is highly leveraged with a debt-to-equity ratio of 6.31, indicating a significant reliance on debt financing.
- The company is unprofitable, with a return on equity of -0.495 and a return on assets of -0.0561.
- Free cash flow and operating cash flow are both negative, indicating ongoing cash burn and liquidity constraints.
- The company's liquidity position is assessed as medium, with a current ratio of 1.24.
- The company's negative net cash position after subtracting total debt is a key flag, indicating a high risk of insolvency.
- There is no clear indication of a turnaround in the near term, with continued losses and negative cash flow.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Pyridam Farma Tbk PT Market data — financials · 2026-05-29